Replimune Group, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026A favorable vote from FDA advisors suggests the company's cancer drug may be closer to approval.
Public presentation to FDA advisors is a key step toward getting approval for a new medicine.
The 10-K shows how much money the company has, spent, and earned over the year.
Earnings announcements tell investors whether the company is making or losing money.
Acceptance by FDA means the company's medicine application is officially back in the approval process.
Resubmission plans show the company is working toward getting approval for its melanoma drug.
A second rejection letter means the company must fix more issues before the drug can be approved.
Stocky reads Replimune Group, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Replimune Group, Inc.'s most recent tracked filing was a 8-K on 31 Jul 2026: FDA advisory committee votes RP1 efficacy results clinically meaningful.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.